NCT04975100View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Major Depressive Disorder
Interventions
DRUG

Sarcosine and SSRI

Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment

DRUG

Placebo and SSRI

Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose

Trial Locations (1)

751019

AIIMS, Bhubaneswar

All Listed Sponsors
lead

All India Institute of Medical Sciences, Bhubaneswar

OTHER

NCT04975100 - Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter